our technology
Esphera designs transgenes encoding multimeric proteins that traffic into budding exosomes.
These multimeric proteins can include extravesicular targeting domains, luminal proteins (antigens, enzymes, adaptors etc) facilitating the packaging of various RNA species (siRNA, mRNA, saRNA).
This allows for the production of, for example, therapeutic exosomes in vivo.
Esphera’s lead application of this platform technology is the modification of tumour cells in vivo such that typically protumourigenic and immunosuppressive tumour-derived exosomes become immunostimulatory, antigen-bearing modifiers of the TME and bespoke, patient specific cancer vaccines.